Kennedy Capital Management LLC Buys Shares of 11,978 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Kennedy Capital Management LLC bought a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,978 shares of the company’s stock, valued at approximately $189,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ZNTL. Quest Partners LLC acquired a new position in Zentalis Pharmaceuticals during the 4th quarter worth approximately $38,000. Tower Research Capital LLC TRC lifted its stake in shares of Zentalis Pharmaceuticals by 252.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after acquiring an additional 2,589 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock valued at $124,000 after acquiring an additional 6,379 shares in the last quarter. 49 Wealth Management LLC bought a new stake in Zentalis Pharmaceuticals during the 1st quarter worth $172,000. Finally, Carson Advisory Inc. bought a new stake in Zentalis Pharmaceuticals during the 1st quarter worth $201,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZNTL. Jefferies Financial Group restated a “hold” rating and set a $6.00 price target (down from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Wedbush lowered shares of Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $15.00 to $4.00 in a report on Tuesday, June 18th. Oppenheimer decreased their price objective on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, June 18th. UBS Group lowered shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $28.00 to $5.00 in a report on Thursday, June 20th. Finally, HC Wainwright dropped their price objective on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $11.33.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.80 on Friday. Zentalis Pharmaceuticals, Inc. has a one year low of $3.27 and a one year high of $29.03. The firm has a 50-day moving average of $6.38 and a 200-day moving average of $10.82.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analysts’ expectations of $35.00 million. During the same period last year, the company earned ($1.07) earnings per share. As a group, sell-side analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.72 EPS for the current year.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the transaction, the chief financial officer now owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the transaction, the insider now owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.